130 related articles for article (PubMed ID: 27943389)
1. The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.
Parham DM; Pinder SE
Histopathology; 2017 May; 70(6):1009-1011. PubMed ID: 27943389
[No Abstract] [Full Text] [Related]
2. Hormonal status might affect outcome in women with HER2-positive ductal carcinoma in situ treated with radiotherapy alone or concurrent radiotherapy plus trastuzumab.
Altundag K
J BUON; 2021; 26(4):1683. PubMed ID: 34565037
[No Abstract] [Full Text] [Related]
3. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
[No Abstract] [Full Text] [Related]
4. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer.
Jasra S; Opyrchal M; Norton L; Mehta R
Clin Breast Cancer; 2017 Feb; 17(1):e37-e41. PubMed ID: 27665021
[No Abstract] [Full Text] [Related]
5. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
6. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
7. HER2 status in residual disease after neoadjuvant treatment might determine sensitivity to trastuzumab emtansine.
Altundag K
J BUON; 2019; 24(4):1736. PubMed ID: 31646835
[No Abstract] [Full Text] [Related]
8. Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study.
Li J; Shao Z; Xu B; Jiang Z; Cui S; Zhang J; Liao N; Jiang J; Wang Y; Ouyang Q; Ying Z
Medicine (Baltimore); 2018 May; 97(21):e10350. PubMed ID: 29794725
[TBL] [Abstract][Full Text] [Related]
9. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).
Gonzalez RJ; Buzdar AU; Fraser Symmans W; Yen TW; Broglio KR; Lucci A; Esteva FJ; Yin G; Kuerer HM
Breast J; 2007; 13(1):72-5. PubMed ID: 17214797
[TBL] [Abstract][Full Text] [Related]
10. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
[TBL] [Abstract][Full Text] [Related]
11. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
[TBL] [Abstract][Full Text] [Related]
13. Should patients with HER2 loss after neoadjuvant treatment still be treated with adjuvant trastuzumab treatment?
Altundag K
J BUON; 2017; 22(4):1085. PubMed ID: 28952236
[No Abstract] [Full Text] [Related]
14. Trastuzumab not for ductal carcinoma in situ?
Nahleh Z; Namakydoust A; Bakkar R; Bishop J
Anticancer Drugs; 2007 Nov; 18(10):1231-5. PubMed ID: 17893526
[TBL] [Abstract][Full Text] [Related]
15. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Hou Y; Nitta H; Wei L; Banks PM; Portier B; Parwani AV; Li Z
Breast Cancer Res Treat; 2017 Nov; 166(2):447-457. PubMed ID: 28799059
[TBL] [Abstract][Full Text] [Related]
16. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis.
Shammas RL; Cho EH; Glener AD; Poveromo LP; Mundy LR; Greenup RA; Blackwell KL; Hollenbeck ST
J Am Coll Surg; 2017 Dec; 225(6):731-739.e1. PubMed ID: 28985927
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
Villarreal-Garza C; Soto-Perez-de-Celis E; Sifuentes E; Ruano S; Baez-Revueltas B; Lara-Medina F; Arce-Salinas C; Alvarado-Miranda A; Chavarri-Guerra Y; Caro-Sanchez C; Castañeda-Soto N; Bargallo-Rocha E; Mohar A
Breast; 2015 Jun; 24(3):218-23. PubMed ID: 25698148
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
19. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
20. Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.
Abramovitz M; Williams C; Loibl S; Leyland-Jones B
Clin Breast Cancer; 2016 Dec; 16(6):444-455. PubMed ID: 27435628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
